GRCL - Gracell Biotechnologies Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.9000
+0.1000 (+3.57%)
At close: 04:00PM EDT
2.9300 +0.03 (+1.03%)
After hours: 07:25PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.8000
Open2.8400
Bid0.0000 x 1000
Ask0.0000 x 3100
Day's Range2.8000 - 2.9000
52 Week Range1.4000 - 5.6910
Volume274,895
Avg. Volume109,411
Market Cap196.374M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3900
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GRCL

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Gracell Biotechnologies to Participate in Jefferies Healthcare Conference

    SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the Jefferies Healthcare Conference on June 8, 2023, in New York, NY. The Gracell team is scheduled to pre

  • Thomson Reuters StreetEvents

    Q1 2023 Gracell Biotechnologies Inc Earnings Call

    Q1 2023 Gracell Biotechnologies Inc Earnings Call

  • GlobeNewswire

    Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd

    SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET. Gracell Biotechnologies’ KOL event will feature participation from management and key

  • GlobeNewswire

    Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

    Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023On track to commence a Phase 1b/2 clinical trial in U.S. and a Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the second quarter and third quarter of 2023, respectivelyLaunched the new IIT evaluating GC012F in systemic lupus erythematosus (SLE)Presenting updated d

  • PR Newswire

    Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company's autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.

  • PR Newswire

    Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online. Clinical data from GC012F, the Company's FasTCAR-enable

  • GlobeNewswire

    Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

    SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two upcoming in-person investor conferences. CICC Healthcare Industry Forum 2023One-on-one & group

  • GlobeNewswire

    Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023

    SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on M

  • PR Newswire

    Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data on GC012F, the Company's FasTCAR-enabled autologous CAR-T cell therapy dual-targeting B-cell maturation antigen (BCMA) and CD19, from ongoing investigator-initiated trials (IIT) in relapsed-refractory multiple myelom

  • GlobeNewswire

    Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022

    SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2022 with the U.S. Securities and Exchange Commission (“SEC”) on April 25, 2023. The annual repo

  • Thomson Reuters StreetEvents

    Q4 2022 Gracell Biotechnologies Inc Earnings Call

    Q4 2022 Gracell Biotechnologies Inc Earnings Call

  • GlobeNewswire

    Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

    Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA clearance for Investigational New Drug (IND) application in January 2023On track to commence Phase 1/2 clinical trial in China evaluating FasTCAR-T GC012F in RRMM in the third quarter 2023 following receipt of NMPA clearance for IND application in February 2023 Continuing patient enrollment and follow-up i

  • PR Newswire

    Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 33rd Annual Healthcare Conference from March 13th to 15th.

  • PR Newswire

    Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the fourth quarter ended December 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, March 13, 2023. The management team will host a live a

  • Simply Wall St.

    Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares Could Be 39% Below Their Intrinsic Value Estimate

    Key Insights The projected fair value for Gracell Biotechnologies is US$3.30 based on 2 Stage Free Cash Flow to Equity...

  • PR Newswire

    Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Gracell's Investigational New Drug (IND) application for GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refracto

  • PR Newswire

    Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the tre

  • Simply Wall St.

    Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) largest shareholders are private equity firms with 34% ownership, insiders own 27%

    To get a sense of who is truly in control of Gracell Biotechnologies Inc. ( NASDAQ:GRCL ), it is important to...

  • Benzinga

    Gracell Biotech's Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates

    Gracell Biotechnologies Inc (NASDAQ: GRCL) announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Patients in the study achieved a 100% overall response rate (ORR) and 100% minimal residual disease (MRD) negativity in all dose levels. Related: Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims. A

  • PR Newswire

    Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the clinical data from its ongoing Phase 1, investigator-initiated trial (IIT) in China evaluating FasTCAR-enabled GC012F as first-line therapy in transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM) patients. Data has been presented in an

  • Benzinga

    Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims

    HC Wainwright initiated coverage on Gracell Biotechnologies Inc (NASDAQ: GRCL) with a Buy rating and a price target of $6. The China-based company is focused on developing autologous and allogeneic CART cell therapies to treat cancer. The analyst notes that Gracell will submit an IND for a potentially registrational study in the U.S. for GC012F (lead program) for relapsed/refractory multiple myeloma by year-end. Related: Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients.

  • PR Newswire

    Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its FasTCAR Autologous CAR-T Platform was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards.

  • GlobeNewswire

    Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

    On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022First clinical data from ongoing investigator-initiated trial (IIT) evaluating GC012F in newly-diagnosed multiple myeloma (NDMM) patients to be presented as oral session at 64th American Society of Hematology Annual Meeting and Exposition (ASH 2022)Continued patient enrollment and follow-up in the ongoing IIT evaluating GC012F in relapsed/refracto

  • PR Newswire

    Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

    Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the first clinical data of its ongoing Phase 1, investigator-initiated study in China evaluating FasTCAR-enabled GC012F in newly diagnosed, transplant-eligible, high-risk multiple myeloma (NDMM) patients. The findings will be presented during an oral session

  • PR Newswire

    Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022

    Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022. The management team will host a live audio webcast a